How Long Can You Stay on HRT?

Somebody has probably given you a number.

Five years is the one most women hear. Others are told to stop at sixty, or at sixty-five, or after a fixed stretch, usually without being told where the number came from or what happens to their symptoms afterwards.

There is no fixed limit in current guidance, and the number you were given was almost certainly not calculated for you.

What replaces the number is less satisfying and more useful: a decision that gets reviewed, on a schedule, against a reason for continuing that has to be stated out loud.

How Long Can You Stay on HRT Before It Has to Be Reviewed?

The 2022 hormone therapy position statement of The North American Menopause Society is the reference point most clinicians work from, and it does not set a maximum duration. What it sets is a process.

The panel states that treatment should be individualized using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing therapy. On duration specifically, it says longer durations of therapy should be for documented indications such as persistent vasomotor symptoms, with shared decision-making and periodic reevaluation.

Read that carefully, because the distinction is the whole page. It does not say stop at a certain point. It says that if you are still on it, there should be a reason on the record, you should have been part of deciding, and the decision should be revisited.

Persistent significant hot flashes at sixty-two can be a documented reason to consider continuing, if the individual benefit-risk assessment still supports it. Still taking it because nobody has reviewed it in six years is not a reason at all, and that is the situation the guidance is written to prevent.

Is Continuing the Same Question as Starting Late?

This is where most of the fear comes from, and it is usually a misreading. The evidence on timing is about when you START.

The position statement puts it in terms of two groups. For women younger than 60, or within 10 years of menopause onset, and without contraindications, the benefit-risk ratio is favorable for treating bothersome vasomotor symptoms and preventing bone loss.

For women who initiate therapy more than 10 years from menopause onset, or who are older than 60, the benefit-risk ratio appears less favorable, because of greater absolute risks of coronary heart disease, stroke, venous thromboembolism and dementia.

Both of those sentences are about initiation. Neither says that a woman who started at 51 must stop at 60.

The practical consequence is that being told to stop because of your age alone is not what the guidance says, and it is worth asking the person telling you which of the two questions they are answering.

Why Do Most Women Stop, and When?

Bunnewell and colleagues pooled 69 studies covering 32,213 women and 2,943 health care professionals, and the picture that emerges is not the one most women expect.

The discontinuation rate was 51.3 percent, with an average duration of 5.4 years. So the familiar five-year figure is real, but as a description of what women do rather than a rule about what they should do.

The reasons matter more than the number. The commonest was a clinician’s recommendation, cited by 31.2 percent, followed by fear about risks at 26.0 percent and a preference for a natural approach at 25.6 percent. Symptom resolution is not what tops that list.

Roughly one in five who stopped restarted, at an average of 20.7 percent, and returning hot flashes were commonly the reason. That is worth knowing before you stop, because it reframes stopping as something that can be tried and reversed rather than a door closing.

What Happens If You Stop?

In the same review, the most commonly reported experiences on stopping were unspecified menopausal symptoms in 84.4 percent, sleep disturbance in 51.9 percent and vasomotor symptoms in 45.4 percent.

Those figures are worth having in advance, because a return of symptoms after stopping is often interpreted as evidence that the body has become dependent on treatment. It is not. It is the underlying symptom becoming visible again once the thing suppressing it is removed.

That also makes stopping genuinely informative. If symptoms do not return, you have your answer about whether to continue. If they return quickly and substantially, that gives you and your clinician useful evidence that the original treatment need is still active and worth reassessing, which is not the same as an automatic case for continuing.

The one thing worth avoiding is stopping without telling anyone, because the information the attempt produces is only useful if someone records what happened.

Should You Taper or Stop Abruptly?

This is the clearest gap between practice and evidence on the whole subject, and it is worth stating plainly rather than repeating the advice.

In the Bunnewell review, 91.6 percent of health care professionals recommended tapered discontinuation, while 62.4 percent of women actually stopped abruptly. Four randomized trials compared the two approaches. Two found that abrupt discontinuers had greater symptoms initially, but that symptoms were comparable to those of taperers once the tapered withdrawal was complete. Two found no difference at all.

Lindh-Åstrand and colleagues ran one of those trials, randomizing postmenopausal women on combined therapy for hot flashes to taper or to abrupt discontinuation, and looked at both symptom recurrence and whether women resumed treatment.

What follows from this is modest and honest. Tapering is reasonable and may make the first weeks easier. It is not a way of avoiding the return of symptoms, and it should not be presented to you as one.

How Do You Decide Whether to Keep Going?

The decision is rarely binary, which is why framing it as stop or continue makes it harder than it needs to be. There is a middle option that gets skipped.

The three questions worth taking to a review.

• Is the reason I started still active, and can I describe what happens without it?
• Has anything changed in my own history, such as blood pressure, a clot, a cancer diagnosis in the family, or a new medication?
• If continuing is right, should the dose or the route be different at my age than it was at the start?

That third question is the one most often missed. Route and dose are adjustable, and adjusting them is a real answer to rising background risk, not a compromise. Our guide to estradiol delivery methods covers what the options actually are.

A review that ends with the same prescription and no discussion is not a review. Neither is one that ends with a stop date and no plan for what happens when symptoms come back.

What Does Tactus Health Do About It?

Our clinicians see women in person at our Sugar Hill, Georgia clinic and by telehealth. Reviewing whether therapy should continue is part of ongoing care rather than a separate appointment you have to request.

In practice that means the reason for treatment is written down and revisited, your history is re-checked against what has changed since you started, and dose and route are treated as adjustable rather than fixed at whatever was chosen first.

We will also tell you when stopping is worth trying. A supervised attempt that answers the question is a better outcome than an indefinite prescription nobody has looked at, and it is reversible if symptoms return.

What we will not do is give you a number of years at the outset, because that number would not be based on anything about you.

Questions Patients Ask Us About How Long to Stay on HRT

Is there a maximum number of years you can take HRT?

Current guidance does not set one. It asks instead that longer use has a documented reason such as persistent hot flashes, that you are part of the decision, and that the decision is reassessed periodically. A fixed limit and a repeated review are different things, and only the second is what the position statement describes.

Do I have to stop HRT at 60 or 65?

Not because of age alone. The caution about being older than 60 is about STARTING therapy at that age, not about continuing therapy that began earlier and is working. Those are separate questions, and being told to stop on age alone is worth querying with whoever advised it.

What happens when you stop taking HRT?

Symptoms commonly return after stopping, although what returns and how strongly varies. In a review of 69 studies, unspecified menopausal symptoms were reported by 84.4 percent, sleep disturbance by 51.9 percent and hot flashes by 45.4 percent. That is the underlying symptom becoming visible again rather than dependence, and about one in five women restart.

Is it better to taper off HRT or stop suddenly?

In the systematic review, 91.6 percent of health care professionals recommended tapering, but the trial evidence does not clearly show it prevents symptoms returning. Of four randomized trials, two found abrupt stoppers had worse symptoms at first but comparable symptoms once tapering finished, and two found no difference. Tapering may ease the first weeks rather than change the outcome.

How often should hormone therapy be reviewed?

Periodically, and with a stated reason for continuing each time. There is no single interval that fits everyone, but a prescription that has been renewed for years without anyone revisiting why is the situation the guidance is written to prevent. Ask when your next review is due if nobody has told you.

Can I go back on HRT if I stop and regret it?

Restarting is common and is not treated as a failure. Around 20.7 percent of women who discontinue resume treatment, with returning hot flashes the usual reason. Framing a stop as something that can be tried and reversed is more accurate than treating it as permanent.

Can you stay on HRT forever?

There is no mandatory stopping age or maximum duration in current guidance. Some women remain on hormone therapy for many years, with a documented reason for continuing and periodic reassessment of benefits and risks. Indefinitely is not the same as unreviewed, and the review is what makes long-term use defensible.

Where does Tactus Health see patients?

In person at our clinic in Sugar Hill, Georgia, and by telehealth. Which states we can see you in depends on the service and on licensure, and it changes, so the current list lives on our telehealth page rather than here where it would go out of date.

Medically Reviewed By

Dr. Ashar N., DNP, APRN, FNP-C, PMHNP-BC

Co-Founder & Medical Director at Tactus Health, and board certified in psychiatric mental health as well as family practice. Clinical focus on hormone therapy, medical weight loss, and aesthetics. Based in Sugar Hill, GA, with telehealth available for eligible patients.